ArticleDrug delivery and translational research2026
Numerical modelling for hollow pyramidal microneedle-based drug-loaded particles delivery for controlled drug release.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The present study develops a comprehensive computational framework to model the coupled transport, deposition, and release behaviour of Ibuprofen-loaded (IBU) core-shell sub-micron particles (MPs) delivered by dual-channel hollow microneedles (HMNs). The model integrates laminar fluid flow within the MN lumen and Darcy-based porous flow in the viable epidermis (VE) and dermis layers of the skin. In addition, the model incorporates advection-diffusion of the dissolved drug (IBU) after release from the core-shell particles, along with Lagrangian particle transport and core- and shell-controlled drug release kinetics. The setup allows simultaneous evaluation of particle transport, deposition, residence time, and spatial drug-release profiles. The effects of polymer chemistry, particle size (2 to 8 μm), dual-channel HMN lumen diameter (40 to 70 μm), and needle array configuration have been systematically investigated. Core and shell particles made of polyvinyl alcohol (PVA), polylactic acid (PLA), and polyglycolic acid (PGA) have been used in this study. It has been found that material and size dependent transport occurs, with PVA shells enabling rapid penetration and early release, whereas PGA shells promote sustained delivery. Smaller particles accumulate and release more drug due to greater penetration through the porous skin microstructure, whereas larger particles exhibit transport limitations. An increase in dual-channel lumen diameter from 40 μm to 70 μm resulted in greater penetration through the porous skin microstructure, whereas larger particles exhibited an 80% rise in particle deposition and a corresponding increase in cumulative IBU release from 18% to 32.4%. Increasing HMN array density enhances parallel transport channels, resulting in a significant increase in drug release from 8% for a single needle to 50.64% for a 4 × 4 array at 500 s, corresponding to a more than six-fold improvement. Overall, this study presents a mechanistic, particle-resolved modelling approach that enhances understanding of HMN-mediated TDD and informs rational system design.
Indexed as
Identifiers
42289613What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.